➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Express Scripts
Dow
Merck
Baxter

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

HERCEPTIN HYLECTA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: HERCEPTIN HYLECTA
Recent Litigation for HERCEPTIN HYLECTA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Pfizer Inc.2019-04-05
Genentech, Inc. v. Samsung Bioepis Co., Ltd.2018-09-04

See all HERCEPTIN HYLECTA litigation

PTAB Litigation
PetitionerDate
GEMoaB Monoclonals GmbH2019-12-20
2018-01-08
2017-12-20

See all HERCEPTIN HYLECTA litigation

Patent Text Search: US Patents for HERCEPTIN HYLECTA

These patents were identified by searching patent claims

Supplementary Protection Certificates for HERCEPTIN HYLECTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C300717 Netherlands   Start Trial PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
CA 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
300728 Netherlands   Start Trial DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
93321 Luxembourg   Start Trial PRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/14/945 - IMBRUVICA - IBRUTINIB
122013000157 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB EMTANSINE; REGISTRATION NO/DATE: EU/1/13/885 20131115
CR 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
1590021-0 Sweden   Start Trial PRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Baxter
Medtronic
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.